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Abstract
Objective—In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) 
infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and 
death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in 
those with negative TST. We examined the cost-effectiveness of IPT in Botswana, where 
antiretroviral therapy (ART) is widely available.
Design—Using a decision-analytic model, we determined the incremental cost-effectiveness of 
strategies for reducing TB and death in 10,000 PLHIV over 36 months.
Methods—IPT for 6 months and provision of ART if CD4+ lymphocyte count <250 cells per 
microliter (2011 Botswana policy) was compared with 6 alternative strategies that varied the use of 
IPT, TST, and ART for CD4+ count thresholds, including CD4+ <350 and <500 cells per 
microliter.
Results—Botswana policy, 2011 was dominated by most other strategies. IPT of 36 months for 
TST-positive PLHIV with ART for CD4+ <250 cells per microliter resulted in 120 fewer TB cases 
for an additional cost of $1612 per case averted and resulted in 80 fewer deaths for an additional 
$2418 per death averted compared with provision of 6-month IPT to TST-positive PLHIV who 
received ART for CD4+ <250 cells per microliter, the next most effective strategy. Alternative 
strategies offered lower incremental effectiveness at higher cost. These findings remained 
consistent in sensitivity analyses.
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Conclusions—A strategy of treating PLHIV who have positive TST with 36-month IPT is more 
cost effective for reducing both TB and death compared with providing IPT without a TST, 
providing only 6-month IPT, or expanding ART eligibility without IPT.
Keywords
cost; cost-effectiveness; tuberculosis; HIV infection; antiretroviral therapy; antituberculosis 
therapy
INTRODUCTION
Antiretroviral therapy (ART) improves survival and reduces the incidence of tuberculosis 
(TB) by approximately 65% in persons living with HIV (PLHIV) while reducing the risk of 
onward HIV transmission to partners. However, in countries with high TB incidence, PLHIV 
receiving ART continue to suffer a high incidence of TB1–3 even when ART is initiated at 
higher CD4+ lymphocyte counts.4,5 Isoniazid preventive therapy (IPT) reduces TB in 
PLHIV both before and after ART initiation.6 Based on a retrospective review of program 
data from Brazil and South Africa and results from two clinical trials, ART in combination 
with IPT additively reduces the risk of TB.7–10
A limitation of IPT is that it benefits only PLHIV who are tuberculin skin test (TST) 
positive,6 but program challenges with the administration and reading of the test have 
prevented strong recommendations to use TST.11,12 Provision of IPT to all PLHIV 
regardless of TST may result in an inefficient use of program resources because 67%–80% 
of PLHIV seen at HIV care centers in TB-endemic countries are TST negative.13–16 A 
further limitation of IPT is that in high TB incidence settings, the standard 6-month course 
loses its benefit within 6–18 months after the IPT stops.17,18 Continuing IPT up to 36 
months has recently been shown to benefit TST-positive PLHIV, including those receiving 
ART,7,19 and World Health Organization (WHO) now recommends a 36-month course of 
IPT where possible.12
Policy makers in countries with high TB incidence have options for reducing mortality and 
morbidity in PLHIV, including earlier initiation of ART and the provision IPT with or 
without a TST for various durations. A key challenge is selecting the most appropriate 
combination of strategies to maximize health benefits, given available resources. 
Researchers have modeled the cost-effectiveness of expanding ART eligibility on survival20 
and TB incidence,21 the cost-effectiveness of providing IPT based on use of TST,22,23 and 
the comparative cost-effectiveness of providing ART versus treating latent TB infection.24 
No model to date compares the cost-effectiveness of policies that concurrently vary ART 
eligibility criteria, the duration of IPT, and the use of TST. We developed a decision-analytic 
model to assist policy makers in selecting cost-effective interventions for responding to the 
TB-HIV syndemic using recent evidence of the impact of ART and IPT on preventing TB 
and death.
Our analysis focused on Botswana for several reasons: (1) 80% of people with TB disease 
are coinfected with HIV in Botswana, (2) primary epidemiological, efficacy, and cost data 
are available from a recently completed clinical trial on 6-month versus 36-month IPT for 
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PLHIV (hereafter, “the Trial”),7 and (3) country-specific ART cost data were available from 
a recently published study.25
METHODS
We developed a decision-analytic model to assess the outcomes, costs, and cost-
effectiveness of strategies for reducing TB disease and all-cause mortality over a 3-year 
analytic horizon in a cohort of 10,000 PLHIV presenting to HIV care clinics in Botswana. 
The model was constructed in TreeAge Pro 2011 (TreeAge, Williamstown, MA).
We calculated costs and outcomes for 7 strategies (Table 1). Each strategy used a 
combination of eligibility criteria for ART initiation (based on CD4+ lymphocyte count 
thresholds), provision of IPT, and use of TST. ART initiation was considered at CD4 <250 
cells per microliter, CD4 <350 cells per microliter, or CD4 <500 cells per microliter. If 
provided, IPT duration was 6 months or 36 months. For the use of TST, we considered 3 
scenarios: provision of IPT to all (without conducting TST), provision of IPT to only those 
with a positive TST, or a targeted approach in which those with negative TST received IPT 
for 6 months and those with positive TST received IPT for 36 months. Although eligibility 
for ART during most of the trial was based on CD4 <200 cells per microliter, the modeled 
“2011 policy” reflects the policy in Botswana toward the end of the trial: TST was not 
performed, PLHIV received 6-month IPT, and those with CD4 <250 cells per microliter 
were eligible for ART.
There were 2 primary outcomes of interest: the expected number of new TB cases 
(incidence) and the expected number of deaths from TB and other causes (all-cause 
mortality). For each strategy, we assumed that CD4 counts were known for PLHIV entering 
the model and that persons with CD4 counts below the specified threshold initiated 
continuous ART; all patients received TB screening at baseline (month 0) using a standard 
clinical symptom screen consistent with Botswana’s national guidelines26,27; and PLHIV 
diagnosed with TB disease were treated according to WHO directly observed therapy short-
course (DOTS) guidelines28 (Supplementary Digital Content, http://links.lww.com/QAI/
A727). False positives—those incorrectly classified as positive for TB disease at screening
—were excluded from the sample of persons eligible for IPT as they would not likely be 
identified as truly negative before completing DOTS. False negatives—those incorrectly 
classified as TB disease-free at screening—were assumed to receive the same clinical care as 
true negatives; however, we assumed they would be correctly diagnosed and begin TB 
treatment within 3 months of screening. Deaths were tabulated for the entire cohort. After 
each 12-month period, the pool of PLHIV without TB disease or death was adjusted 
downward to account for those who developed TB or died in the previous period.
Efficacy and Other Epidemiological Parameters
The model uses primary data and key results from the trial. The randomized, double-blind, 
placebo-controlled trial enrolled adults with HIV infection who attended one of 8 
government clinics that provided ART and IPT in Gaborone and Francistown, Botswana, 
between November 26, 2004 and July 20, 2006.7 Required inputs unavailable from trial data 
were abstracted from the literature or imputed, when necessary.
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TB disease prevalence at baseline by CD4 strata and expected number of PLHIV requiring 
hospitalizations for TB and isoniazid toxicity was estimated using trial data and published 
sources.1,29 For each CD4 stratum, we used published data to estimate the number of 
PLHIV falsely classified positive or negative for TB disease given prevalence and 
assumptions about screening sensitivity and specificity.1,29,30 For each CD4 stratum, we 
estimated rates of TST positivity separately for those with and without prevalent TB based 
on abstracted data from published materials.14,16,31–34
We used unadjusted rates of incident TB and death from the trial’s intent-to-treat analysis to 
determine the efficacies of ART and IPT, ie, no adjustment was made for losses to follow-up 
or nonadherence to study medication or ART. We derived model estimates of TB incidence 
and death rates using higher thresholds for the ART initiation literature (Table 2). In model 
scenarios based on initiating ART at higher CD4 cell counts, we accounted for reductions in 
incident TB disease and death because of higher median CD4 counts in the eligible portion 
of the cohort.1 In trial data, the reduction in TB and death due to IPT varied according to 
duration (6 or 36 months), the progression of HIV disease, the concomitant provision of 
ART, and TST status. We accounted for each of these factors in the model. In strategies in 
which IPT was provided without TST results, rates of TB and death by TST status from the 
trial were averaged and weighted by the observed number of TST positives (0.25) and TST 
negatives (0.75). Further information on the derivation of key efficacy parameters can be 
found in the Supplementary Digital Content, http://links.lww.com/QAI/A727.
Cost Inputs
We adopted a Botswana health system perspective and included relevant health care 
utilization costs (Table 2). We did not include out-of-pocket costs incurred by individuals, 
productivity loss from illness or death, or costs that were identical under each strategy. The 
time frame and analytic horizon for the analysis were 36 months. The total cost of each 
strategy was calculated by multiplying the total number of individuals using each service (ie, 
TST, IPT, ART, TB treatment, and hospitalizations) by the associated unit cost and summing 
across all services. All costs have been adjusted to 2010 US dollars.35
Cost per patient for TST consisted of health care personnel labor, average cost per dose of 
purified protein derivative-TST, medical supplies, and necessary investment costs, including 
health worker training and refrigeration for purified protein derivative. Labor cost for 
administration and reading of TST was calculated as nurse time devoted to patient testing 
multiplied by the median wage rate. Cost per patient of both IPT and TB treatment was 
calculated as the sum of drug costs and health worker time for administration and 
monitoring of therapy (assuming monthly follow-up visits for IPT and daily pharmacist 
observation for DOTS).27 The cost per patient for hospitalization was calculated by 
multiplying the average number of inpatient days (21 for TB disease and 10 for isoniazid 
toxicity) by the average hospitalization cost per day.36
The annual cost per patient of clinical care for ART (clinic visits and laboratory monitoring) 
was taken from the President’s Emergency Plan for AIDS Relief Botswana ART cost 
study.25 Annual per-patient antiretroviral costs were calculated using drug prices and 
regimen distribution data provided by the Supply Chain Management System for President’s 
Smith et al. Page 4













Emergency Plan for AIDS Relief. We assumed that 3% of patients required second-line 
ART. All PLHIV received similar care before initiating ART. To account for costs associated 
with ART initiation, we applied only the incremental cost of antiretrovirals and added 
intensity of clinical care required to monitor patients receiving ART. For each strategy, we 
adjusted the total cost of ART upward to account for the proportion of the cohort above the 
specified CD4 threshold that would become eligible and initiate ART over the 36-month 
period.37 ART costs were also adjusted downward for patients who died within the analytic 
horizon, as the health system would not incur costs for the full 36 months of ART.
Cost-Effectiveness Analysis
We conducted cost-effectiveness analysis separately for each outcome measure. We 
evaluated the expected number of TB cases, deaths, and total cost for each strategy and 
ranked them in order of increasing effectiveness. We computed the incremental cost-
effectiveness ratios (ICERs) for each outcome by taking the difference in total costs divided 
by the difference in cases or deaths when comparing one strategy to the next most effective. 
The final ICERs excluded strategies that were both less effective and more costly than others 
(ie, absolutely dominated strategies). Strategies with higher ICERs than more effective 
alternatives (ie, extended dominated) were similarly excluded.38
Sensitivity Analysis
We varied cost inputs by 50% above and below their base values in the sensitivity analysis. 
To identify influential model parameters, we conducted tornado analyses for each outcome 
across a range of arbitrary willingness-to-pay (WTP) thresholds.39 In the absence of well-
documented WTP thresholds for each outcome measure, we considered a wide range of 
values of WTP. For influential model parameters, we conducted additional univariate 
sensitivity analysis to determine whether the rank of optimal strategies would change at any 
value from the specified range.
RESULTS
Expected outcomes (incident TB and all-cause mortality), total costs, and ICERs are 
presented in Table 3.
Incident TB
Considering incident TB cases averted as the primary outcome, 4 strategies were both less 
effective and more costly than other alternatives (Fig. 1) and were excluded from the 
incremental analysis. These included providing IPT to PLHIV for 6 months (2011 policy, 
ALL_H6), providing IPT to all PLHIV for 36 months (ALL_H36), and both strategies that 
increased the threshold for ART initiation without the provision of IPT (ART350 and 
ART500).
Treating only PLHIV with a positive TST with 6-month IPT and initiating ART at CD4 
<250 cells per microliter (TST_H6) were the least costly but least effective of the remaining 
strategies (Table 3, upper panel). Comparatively, extending IPT to 36 months for TST-
positives (TST_H36) resulted in 120 fewer cases for an additional $1612 per case averted 
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when compared with the next most effective strategy (TST_H6). The strategy of providing 
TST-negatives with a 6-month course of IPT and TST-positives with a 36-month course 
(TST_H6H36) resulted in 27 fewer cases for an additional $6549 per case averted compared 
with the next most effective alternative (TST_H36).
Four parameter categories accounted for at least 85% of variation in model results across all 
WTP thresholds in the sensitivity analysis. At a WTP threshold of $10,000, the per-patient 
cost of ART and percent of the cohort below CD4 250 cells per microliter accounted for 
55% and 30% of the variation, respectively. At a $1,000,000 WTP threshold, the effect of 
ART and the effect of higher CD4 count had a greater impact, accounting for 64% and 27% 
of the variation. The rank-order of undominated strategies remained consistent at all values. 
Additional detail on sensitivity analysis results is in the Supplementary Digital Content, 
http://links.lww.com/QAI/A727.
All-Cause Mortality
Considering mortality as the primary outcome, providing 36-month IPT to all PLHIV 
(ALL_H36) was less effective than all other strategies and more costly than all alternatives 
that included IPT and was excluded from the incremental analysis (Fig. 2). Two strategies—
providing 6-month IPT to all PLHIV and initiating ART at CD4 <250 cells per microliter 
(2011 Botswana policy, ALL_H6) and increasing the CD4 threshold for ART initiation to 
<350 cells per microliter without IPT (ART350)—had higher ICERs than more effective 
alternatives and were also excluded. Similar to the results for incident TB, providing 6-
month IPT for TST-positives only (TST_H6) was the least effective and least costly 
alternative of those not dominated.
Compared to providing 6 months of IPT, extending the duration of IPT to 36 months for 
TST-positives (TST_H36) resulted in 80 fewer deaths for an additional $2418 per death 
averted compared with the next most effective strategy (TST_H6) (Table 3, lower panel). 
Adding 6-month IPT for TST-negatives (TST_H6H36) resulted in 3 fewer deaths at a cost of 
$58,944 per death averted when compared with the next most effective alternative 
(TST_H36). Discontinuing IPT and increasing the threshold for ART initiation to CD4 <500 
cells per microliter (ART500) were both the most effective and most costly alternative, 
resulting in 47 fewer deaths than TST_H6H36 at an additional $77,694 per death averted (in 
comparison with TST_H6H36) among the undominated strategies.
From our sensitivity analysis with mortality as the outcome, we found that 4 parameter 
categories accounted for more than 90% of variation across all WTP thresholds. Per-patient 
cost of ART, percent of the cohort below CD4 250 cells per microliter, effect of ART, and 
effect of initiation of ART at higher CD4 count were the same 4 parameters that accounted 
for most of the variation when incident TB was the outcome. There was no change in the 
rank-order of undominated strategies; however, ART500 becomes dominated when the 
effect of ART is reduced by 28% or more or the effect of higher threshold CD4 count is 
reduced by 11% or more. Conversely, TST_H6H36 is dominated when the effect of ART is 
increased by 18% or more, or the effect of higher threshold CD4 count is increased by 10% 
or more. TST_H6H36 is also dominated when more than 47% of the cohort has a CD4 count 
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<250 cells per microliter or the annual cost per patient of ART (inclusive of drugs) is less 
than $271.
DISCUSSION
Our cost-effectiveness analysis of several strategies for the prevention of TB and death in 
PLHIV in Botswana suggests that strategies that use TST in conjunction with continuous 
IPT and ART are superior to providing 6-month IPT and ART for PLHIV with CD4 <250 
cells per microliter, which was the current strategy at the time of this study. Treating TST-
positive PLHIV with 36-month IPT is more cost-effective than providing IPT without a TST, 
providing only 6-month IPT or expanding ART eligibility with no IPT. Our results are not 
surprising given the benefits of continuous IPT demonstrated in the trial. Although we 
cannot conclude definitively which strategy is most cost effective—an assessment that 
requires an understanding of the WTP for additional TB cases or deaths averted—we can 
submit that strategies including the provision of 36 months of IPT for TST-positive PLHIV 
resulted in the highest number of TB cases and deaths averted for the least cost. These 
findings remain pertinent to the current situation in Botswana: in 2014, the Ministry of 
Health policy is to provide ART at a threshold of 350 cells per microliter and 6 months of 
IPT without the use of the TST.
Although the model results clearly favor strategies that include provision of IPT, the 
importance of ART should not be downplayed. Both ART and IPT have significant impacts 
on TB incidence, whereas death is reduced by ART and may be reduced by IPT in PLHIV 
with positive TSTs.7,40 Our analysis showed that although death and TB incidence declined 
in PLHIV receiving ART at higher CD4 levels, early ART strategies were either far more 
costly or dominated by those that added continuous IPT for persons with positive TST while 
providing ART at the lower CD4 <250 cells per microliter threshold. Because there are other 
important reasons to provide early ART not captured by this model (for example, impact on 
HIV transmission), IPT should be considered a cost-effective adjunct to ART. Despite living 
in a setting with high TB incidence, PLHIV who were TST-negative have been observed to 
have a steady ~1% per annum rate of TB despite provision of ART for CD4 <200 cells per 
microliter and 6-month IPT.7 Strategies that provided IPT to all PLHIV including TST-
negative PLHIV were dominated by strategies that targeted IPT to TST-positive PLHIV.
Based on our results, TST is a critical component for allocating resources efficiently. In 
other settings, approximately 3-quarters of PLHIV screened in TB-endemic settings were 
documented as TST-negative7,13,41,42 and are unlikely to benefit from IPT. Additionally, 
they may be subjected to the adverse effects of IPT. Our results are congruent with findings 
from other TST studies. In a voluntary counseling and testing center setting in Uganda, TST 
before 6 months of IPT was found to be cost effective compared with not using TST.22 A 
recent example from a Thai program concluded that limiting IPT to TST-positive PLHIV 
receiving ART was practical and effective.43 Program managers and WHO officials remain 
concerned that TST is difficult to implement in resource-constrained settings. Given the 
cost-effectiveness of IPT provision based on TST, programs should include plans to mitigate 
operational challenges, including training networks that enable outreach workers to read 
TST results consistently, in a system including routine quality checks.
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Resistance to anti-TB drugs is a concern and could impact interpretation of our results in 2 
ways: accidental provision of IPT to persons with active TB disease may lead to isoniazid 
resistance and high rates of latent isoniazid-resistant TB infection may influence the 
effectiveness of preventive therapies. No increased risk of isoniazid resistance was observed 
in the 2000-person cohort followed in the Botswana trial. However, our findings reflect the 
effectiveness of IPT in Botswana at the time of the trial and might not extend to situations 
with higher background rates of latent isoniazid-resistant infection; this may be a subject for 
future investigation.
A key strength of our model is the stability of results in sensitivity analysis. When we varied 
the CD4 range of the enrolled cohort, the cost-effectiveness rank order of alternative 
strategies was constant. The stability provides a sense of generalizability for places where 
there are higher or lower proportions of TST-positivity, as TST-positivity rates are higher 
among PLHIV with higher CD4 counts. The priority order of the 7 strategies did not change 
when varying model parameters to their upper and lower bounds across a range of WTP 
thresholds, indicating results may be generalizable to other low-income and middle-income 
settings with similar TB-HIV burden.
Limitations of our analysis include a possible underestimation of the mortality benefit of IPT 
given that 2 reports have shown reductions in mortality in PLHIV receiving 6 months IPT in 
ART programs.40,44 We did not consider the risk of multidrug-resistant TB (ie, resistance to 
isoniazid and rifampin) or the associated costs of second-line or third-line anti-TB therapies. 
We did not consider how TB prevention in the cohort might affect TB transmission, nor did 
we include other possible approaches, such as implementation of infection control practices 
that might also reduce the risk of TB infection. Our choice of a 3-year analytic horizon 
reduces the complexity of the model; however, it does not allow us to account for outcomes 
related to the likelihood of developing TB after IPT is discontinued at 36 months. We 
focused on prevention of TB and all-cause mortality, whereas early provision of ART may 
also reduce HIV transmission, lifetime health care costs, and productivity loss. Although the 
perspective of our analysis allows us to focus on the direct costs of diagnosis and treatment, 
it does not account for the potential benefits to society resulting from averting TB-related 
morbidity and mortality. Our analysis addresses epidemiologic and economic considerations 
for a middle-income country with high TB incidence and may not be generalizable to other 
settings.
In TB-endemic settings in which ART is already provided for CD4 <250 cells per microliter, 
a policy of treating TST-positive PLHIV with 36-month IPT is more cost effective than 
providing IPT without a TST, providing only 6-month IPT, or expanding ART eligibility 
with no IPT. Compared with ART initiation at higher CD4 thresholds, the strategy of 
treating TST-positive PLHIV with 36-month IPT is the most cost-effective approach to 
reduce TB disease and death.
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Expected cost and all-cause mortality among 7 strategies in 10,000 PLHIV in Botswana.
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ALL_H6 2011 policy in Botswana—provide all PLHIV with 6-mo
IPT and initiate ART at CD4 <250 cells/µL
ALL_H36 Provide all PLHIV with 36-mo IPT and initiate ART at
CD4 <250 cells/µL
TST_H6 Provide only TST-positive PLHIV with 6-mo IPT and
initiate ART at CD4 <250 cells/µL
TST_H36 Provide only TST-positive PLHIV with 36-mo IPT and
initiate ART at CD4 <250 cells/µL
TST_H6H36 Provide all PLHIV with 6-mo IPT, extend duration to 36
mo for TST-positives, and initiate ART at CD4 <250
cells/µL
ART_350 Discontinue IPT and increase ART initiation threshold for
PLHIV from CD4 <250 cells/µL to <350 cells/µL
ART_500 Discontinue IPT and increase ART initiation threshold for
PLHIV from CD4 <250 cells/µL to <500 cells/µL
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